Business Context and Reporting Period
This Form 10-Q covers Eli Lilly and Company for the quarter ended March 31, 1999. The company operates primarily in pharmaceutical products, with animal health operations deemed immaterial. A significant event during the period was the sale of its health-care-management subsidiary, PCS, to Rite Aid Corporation for $1.6 billion in cash, which closed on January 22, 1999. Consequently, PCS results are reported as discontinued operations.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Net Sales | $2,255.6 million | $2,087.0 million |
| Net Income | $625.7 million | $521.1 million |
| Diluted EPS | $0.56 | $0.46 |
| Gross Margin | 78.1% | 78.1% |
| Effective Tax Rate | 17% | 24.4% (implied) |
| Cash and Equivalents | $2,404.4 million | $1,264.7 million (end of period) |
| Total Debt | $2,338.9 million | N/A (Balance sheet data not provided for Q1 1998) |
| Operating Cash Flow | ($109.2 million) | $57.3 million |
Note: Net income includes a $174.3 million gain from discontinued operations (PCS sale). Excluding non-recurring items and discontinued operations, net income increased 12% and EPS increased 15% compared to the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% year-over-year, driven by a 10% volume increase. Worldwide pharmaceutical sales rose 9% to $2.11 billion.
- Product Performance: Sales growth was led by Gemzar (+101%), Zyprexa (+40%), ReoPro (+44%), and Humalog (+72%). These gains were partially offset by declines in Prozac (-4%), anti-infectives (-15%), and Axid (-23%).
- Discontinued Operations: The sale of PCS generated a pre-tax gain of $174.3 million, significantly boosting net income and EPS by $0.16.
- Special Charges: The quarter included a $61.4 million asset impairment charge related to manufacturing assets and a $150.0 million pre-tax charge for funding commitments to the Eli Lilly and Company Foundation.
- Cash Flow: Operating cash flow turned negative ($109.2 million outflow) compared to a positive $57.3 million in 1998, primarily due to changes in operating assets and liabilities. However, investing cash flow was strongly positive ($1.56 billion) due to PCS proceeds.
Guidance, Outlook, and Risks
- Prozac Outlook: Management anticipates slight growth in worldwide Prozac sales for the full year, though U.S. sales face pressure from generic competition and wholesaler inventory reductions expected to continue into Q2.
- New Product Growth: Continued strong sales growth is expected for Zyprexa and Evista in 1999.
- Liquidity: Management believes cash generated from operations, combined with existing cash reserves, will fund all 1999 operating needs, debt service, capital expenditures, share repurchases, and dividends.
- Legal Risks: Significant litigation exists regarding Prozac patents. Six generic manufacturers have challenged the validity of Lilly's patents. While the company believes it will prevail, an unfavorable outcome could materially adversely affect financial position and results.
- Year 2000 (Y2K): The company estimates total Y2K remediation costs between $160 million and $180 million, with 65-70% incurred by March 31, 1999. Failure to achieve compliance could materially disrupt operations.
- Accounting Changes: The company adopted SOP 98-5 regarding start-up costs (immaterial impact) and is evaluating the impact of SFAS No. 133 on derivative instruments.
Investor Verification Checklist
- Verify the status and potential financial impact of the Prozac patent litigation against six generic manufacturers.
- Confirm the extent of wholesaler inventory destocking for Prozac and Evista in Q2 1999.
- Review the progress of Year 2000 remediation for critical IT and non-IT systems to assess operational risk.
- Monitor the sustainability of sales growth for new products (Zyprexa, Gemzar, ReoPro) as they mature.
- Assess the impact of the $150 million foundation funding charge on future discretionary spending or earnings.